Tracon Pharmaceuticals, Inc. has achieved a significant regulatory milestone with the United States Securities and Exchange Commission (SEC) declaring a Notice of Effectiveness on November 1, 2024. The document, bearing the Accession Number 0000950170-24-119574, was submitted under the type POS AM, indicating an amended post-effective amendment. This notice marks a key step for Tracon Pharmaceuticals, allowing the company to proceed with actions that were contingent on the SEC's approval.

Tracon Pharmaceuticals, Inc. has achieved a significant regulatory milestone with the United States Securities and Exchange Commission (SEC) declaring a Notice of Effectiveness on November 1, 2024. The document, bearing the Accession Number 0000950170-24-119574, was submitted under the type POS AM, indicating an amended post-effective amendment. This notice marks a key step for Tracon Pharmaceuticals, allowing the company to proceed with actions that were contingent on the SEC's approval.